High expression of CIP2A contributes to imatinib resistance in CML and is a strong prospective predictor of subsequent development of BC in imatinib-treated patients.5 However the mechanism(s) by which CIP2A increases the risk of disease progression is poorly understood. The gene discussed is CIP2A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.